Cut-price drug venture takes aim at Pfizer and Astrazeneca
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
A blockbuster breast cancer niche has Roche and Sanofi in the lead
As SAR439859 and RG6171 move into pivotal testing, the Serd approach to treating one form of breast cancer generates renewed interest.
Esmo 2019 preview – Parps on parade
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.
G1 makes the most of trilaciclib's unclear survival benefit
G1 Therapeutics fast-tracks what it says is the first CDK4/6 inhibitor aimed at reducing chemotherapy-induced myelosuppression.
Another huge quarter for biotech flotations
Another billion dollar quarter for biotech IPOs signals that investor appetite for high-risk offerings is strong.
